- Home
- PLG vs CGEN Comparison
PLG vs CGEN Comparison
Compare PLG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLG | CGEN |
|---|---|---|
| Founded | 2000 | 1993 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.4M | 191.1M |
| IPO Year | 2002 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PLG | CGEN |
|---|---|---|
| Price | $1.28 | $2.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 888.1K | 251.2K |
| Earning Date | 04-10-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $1.30 |
| 52 Week High | $4.04 | $3.24 |
Technical Indicators
Market Signals| Indicator | PLG | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 47.52 |
| Support Level | $1.25 | $2.22 |
| Resistance Level | $1.48 | $2.35 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 39.13 | 16.18 |
Price Performance
Historical ComparisonAbout PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.